Abstract 577P
Background
Dysbiosis of the fecal microbiota has been closely related to colorectal cancer (CRC) and has increasingly proven to be associated with CRC prognosis. However, a significant knowledge gap still exists regarding intestinal tissue-resident microbes and their associations with host genetic alterations, gene expressions and prognosis in CRC.
Methods
We undertook a comprehensive analysis of the tissue-resident microbes in CRC patients from the U-CAN cohort, a large prospective longitudinal study of adult cancer patients in Sweden, using treatment-naïve whole-genome (average 53x coverage) and whole-transcriptome sequencing data of tumors (n=937) and their adjacent normal tissues (n=475).
Results
In total, 301 genera and 420 species were identified as common tissue-resident taxa. We showed for the first-time distinct enrichment patterns of tissue-resident microbiome in the right- and left-sided colons. Importantly, these patterns were highly consistent between tumor and normal tissues, with right-sided colons enriched with Clostridium spp and left-sided colons enriched with Akkermansia muciniphila and Bifidobacterium spp. We identified 94 tumor-enriched bacteria, and 38 were significantly associated with host hypermutation (HM) status. Previously known CRC-enriched bacteria, such as Fusobacterium groups and Campylobacter, were more prevalent in right-sided and HM tumors, and strongly correlated with mutations in host drivers and DNA damage repair genes. CRC driver genes that correlated with identified intratissue bacteria including CASP8, TP53 and SMAD2, with CASP8 significantly associated with multiple CRC-enriched taxa in all and in HM samples. Finally, risk scores derived from tumor or normal-resident taxa could both predict CRC prognosis and significantly improve the prognosis performance of the consensus molecular subtypes (CMS).
Conclusions
Our study provides new insights into the interactions between tumor-enriched microbiota with CRC and identifies potential bacteria markers that could improve the accuracy of CRC prognosis prediction. These findings can guide future efforts to exploit the performance of intratissue bacteria on CRC prognosis prediction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Uppsala University, Umea University, BGI-Shenzhen.
Funding
The Swedish Cancer Society, the Uppsala Cancer Foundation, the Guangdong Provincial Key Laboratory of Human Disease Genomics, the Swedish Government (CancerUU), the Erling-Persson Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The effect of exercise intervention on defecation related symptoms of colorectal cancer patients a randomized controlled trial
Presenter: Justin Jeon
Session: Poster session 10
582P - High accuracy of a blood-based multimodal ctDNA test to detect advanced neoplasms in a FIT-positive screening population
Presenter: Joana Vidal Barrull
Session: Poster session 10
583P - A rapid blood test for the earlier detection of colorectal cancer
Presenter: Jennifer Nobes
Session: Poster session 10
584P - Two-year update of the prospective evaluation of ColonAiQ (PreC) study
Presenter: Yanbing Ding
Session: Poster session 10
585P - Fragmentomics early detection assay leading to potential clinical benefits in colorectal cancer
Presenter: Yuepeng Cao
Session: Poster session 10
586P - Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Presenter: Daphne Day
Session: Poster session 10
588P - PLCRC-PROVENC3 study: Prognostic value of post-surgery liquid biopsy circulating tumor DNA in stage III colon cancer patients
Presenter: Carmen Rubio-Alarcón
Session: Poster session 10
589P - Impact of landmark point selection on molecular residual disease detection in stage I-IV resectable colorectal cancer
Presenter: Di Cao
Session: Poster session 10
590P - Assessment of circulating tumor (ct)DNA in patients (pts) with locally advanced rectal cancer (LARC) pts treated with neoadjuvant therapy (NAT)
Presenter: Chiara Molinari
Session: Poster session 10